The global Genome Engineering Market is projected to be valued at USD 3.19 Billion in 2017 and is expected to grow at a CAGR of 14.5% to reach to USD 6.28 Billion by 2022.

Thermo Fisher Scientific (US) is the leading player in the global genome editing market. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. The company’s business segments include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. To maintain its position and increase its customer base in the Genome Engineering Market, the company mainly focuses on expanding its market presence by adopting growth strategies, such as acquisitions, partnerships, and collaborations. For instance, in July 2016, Thermo Fisher partnered with healthBioMed (HBM) (China) to support HBM in the development of molecular diagnostics kits. Through this partnership, HBM aimed to develop pharmacogenomics kits and support the precision medicine initiative in China. Furthermore, in March 2016, Thermo acquired Affymetrix (US) to enhance its product portfolio. Moreover, the company invests in R&D activities to increase its depth of capabilities in technologies, software, and services. It invested 5.0%, 4.08%, and 4.09% of its total revenue in 2016, 2015, and 2014, respectively in R&D activities.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000

Merck (Germany) held the second-largest in the genome editing market. The company has gained a major share in the market on account of its diversified product portfolio, widespread geographical presence, and focus on strategies such as expansions. In recent years, the company has witnessed tremendous growth in revenue in the genome editing business by pursuing the strategy of expansions to strengthen its business position in the Genome Engineering Market.

Horizon Discovery Group (UK) is another prominent player in the Genome Engineering Market. The company is a leading supplier of genetically defined cell lines, reporter gene assay kits, genomic reference standards, and contract research services. With a diversified product portfolio, wide geographical reach, and focus on inorganic strategies such as acquisitions, collaborations, and agreements, the company has succeeded in creating a strong foothold in the Genome Engineering Market. For instance, in January 2015, Horizon Discovery acquired Haplogen Genomics GmbH, a biotechnology company based in Vienna, Austria. The acquisition provided Horizon with a cell line generation platform.

Objectives of the Study:

• To define, describe, and forecast the global genome editing/engineering market on the basis of technology, application, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To forecast the size of market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To analyze the market structure, profile key players of the global genome editing/engineering market, and comprehensively analyze their core competencies
• To track and analyze competitive developments such as partnerships, agreements, collaborations, expansions, acquisitions, and product & service launches in the market

Related Links: https://www.marketsandmarkets.com/ResearchInsight/genome-editing-engineering-market.asp

https://www.marketsandmarkets.com/PressReleases/genome-editing-engineering.asp